← Eichor
Study identifier: NCT07638007 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

Condition: Disease/Condition Name Cancer-related Cognitive Dysfunction · Chronic Lymphocytic Leukemia (CLL) · Chronic Myeloid Leukemia, BCR-ABL1 Positive  ·  Sponsor: University of Rochester NCORP Research Base

PhaseN/A
Planned participants400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Ashley Mack, MS  ·  585-275-1090  ·  URCC_24060@urmc.rochester.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Rochester NCORP Research BaseRochester, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07638007